Notice/News
Notice/News
Number
Title
Date
1
[IR Pharm] A New Paradigm in Gene Editing③: The Aesthetics of Paradox: The Longer the Dispute, the Deeper the ‘Monopoly’… ToolGen’s IP Monetization Strategy
2026.05.06
2
[IR Pharm] A New Paradigm in Gene Editing②: From the Lab to the Courtroom… Opening Salvo in the IP Battle to Determine Ownership of ‘CRISPR Tolls’
2026.05.05
3
[IR Pharm] A New Paradigm in Gene Editing①: The End of Statistics, the Age of Mechanisms… An Unprecedented Opportunity for ToolGen Amid FDA Regulatory Revolution
2026.05.04
4
[Notice] U.S. Patent Registration Certificate (US 12,612,632 / US 12,612,633 / US 12,612,634)
2026.04.28
5
[Notice] CRISPR RNP Patent Status update(US,EU)
2026.04.28
6
[Notice] CRISPR RNP Patent Status update(US,EU)
2026.04.21
7
[Notice] U.S. CRISPR RNP Patent Granted_US 12,606,832 B2
2026.04.21
8
[Notice] The Priority Phase of Interference No. 106,126 between ToolGen and the Broad Institute has resumed
2026.03.31
9
[Notice] March 26, 2026 PTAB Decision: Summary and Outlook
2026.03.30
10
[edaily] “ToolGen’s Yoo Jong‑sang Says CRISPR‑Cas9 Patent Battle Heats Up in H2, With Rising Pressure for a Three‑Party Deal”
2026.03.26
11
[Notice] ToolGen to Form Science Advisory Board (SAB)
2026.03.25
12
[Notice] CRISPR RNP Patent Status update(US,EU)
2026.03.18
13
[Finance Economy Plus] “Patents are the sword; royalties are the shield” — ToolGen declares 2026 its inaugural year for monetizing gene‑editing “scissors.”
2026.02.18
14
[Press Release] ToolGen Enters 'Harvest Season' for Global IP Monetization ; Appoints Litigation & Negotiation Expert Dave Koo as CLO
2026.02.12
15
[Notice] CRISPR RNP Patent Status update(US,EU)
2026.02.04